Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746483 · ClinicalTrials.gov registry record · Phase 2
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
A Phase 2 study, sponsored by Entero Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT03746483 is a Phase 2 study that has completed, run by Entero Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT03746483, a Phase 2 study, has completed, sponsored by Entero Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
Interventions
- DRUG MS1819
- DRUG Porcine PERT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2019-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746483
The ClinicalTrials.gov registry entry for NCT03746483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Entero Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MS1819 is the first listed.
NCT03746483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03746483 about?
NCT03746483 is a clinical study titled "OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis". The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
What is the current status of trial NCT03746483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2019-01-10. Estimated completion is 2019-07-27.
What interventions are being tested in trial NCT03746483?
The interventions under investigation include: MS1819 (DRUG), Porcine PERT (DRUG).
Who is sponsoring clinical trial NCT03746483?
This trial is sponsored by Entero Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.